Apollo Medical Holdings, Inc. Announces Appointment of Chief Strategy and CFO Transition Officer
ALHAMBRA, Calif., May 5, 2022 /PRNewswire/ — Apollo Medical Holdings, Inc. (“ApolloMed” and, together with its subsidiaries and affiliates, the “Company”) (NASDAQ: AMEH), a leading physician-centric healthcare company focused on on technology service providers in the successful delivery of value-based care, today announced the appointment of chan basho to the newly created position of Chief Strategy Officer. Mr Basho will also assume the role of Acting Chief Financial Officer as Eric Chin resigned as CFO for personal reasons. Mr. Chin will continue to work with the Company as an executive advisor to ensure a smooth transition.
As Chief Strategy Officer, Mr. Basho will work closely with the Company’s Co-CEOs to lead the development and execution of ApolloMed’s strategy and operations, as well as improving operational discipline. to ensure the company’s ability to evolve successfully.
BrandonSim, co-CEO of ApolloMed, said, “We are delighted to welcome Chan as Chief Strategy Officer and Interim Chief Financial Officer at ApolloMed. prove increasingly valuable as our company moves forward with its plans for future growth. Chan has a deep understanding of and commitment to our mission to cost-effectively deliver quality healthcare to our local communities, and our team is excited to work closely with him in this important new role. I would like to thank Eric on behalf of the entire ApolloMed management team for his professionalism, expertise and many contributions over the past few years. He was instrumental in developing our internal financial controls and spearheading our capital allocation, corporate finance and communications strategies. We wish him the best of luck and greatly appreciate his support during this transitional journey.”
Mr. Basho commented, “I am delighted to join ApolloMed during this critical and exciting time in the company’s history. I look forward to working closely with Brandon and management to advance the company’s strategy and mission to enable providers across the country to successfully deliver value-based care and improved outcomes for our members. I am honored to have this opportunity to help ApolloMed continue to build on its impressive 25-year legacy.
Mr. Basho has 15 years of experience in strategy, finance and operations in well-known healthcare companies, having most recently served as Vice President of Strategy and Corporate Development at Alignment Healthcare since 2018. From 2017 in 2018, Mr. Basho served as Chief Financial Officer. at Alsana, a behavioral health company backed by private equity. From 2014 to 2017, Mr. Basho held various positions at HealthCare Partners, a DaVita Medical Group company, including as Vice President of Strategy and Corporate Development, Head of Strategy and Development for the California market. From 2007 to 2014, Mr. Basho held various strategy and finance related roles at DaVita Kidney Care, including as Director of Corporate Finance. Mr. Basho earned a bachelor’s degree in biological engineering from the University of California, Berkeleyand an MBA from the Wharton School at University of Pennsylvania.
About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-focused, technology-driven, and risk-taking healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care agreements, enabling them to deliver care of high quality to patients in a cost effective manner.
Based at Alhambra, California, ApolloMed’s subsidiaries and affiliates include Management Service Organizations (MSOs), Independent Practice Associations (IPAs) affiliates, and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models . For more information, visit www.apollomed.net.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company’s continued growth, operating direction and strategic growth plans. Forward-looking statements reflect current views regarding future events and financial performance and therefore cannot be guaranteed. These statements are based on the current expectations and certain assumptions of the Company’s management, and some or all of these expectations and assumptions may not materialize or may differ materially from actual results. Actual results may also differ materially from forward-looking statements due to known and unknown risks, uncertainties and other factors, including the risk factors described from time to time in the Company’s filings with the SEC, including including, without limitation, the risk factors discussed in the company’s annual report on Form 10-K for the fiscal year ended December 31, 2021filed with the SEC and all subsequent quarterly reports on Form 10-Q.
FOR MORE INFORMATION PLEASE CONTACT:
Caroline SohnThe Equity Group
SOURCEApollo Medical Holdings, Inc.